EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Äquivalenzstudie

Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block

Yujun Zhang, Yingying Jiang, Qian Lei, Chaoyu Li, Shu'an Jin, Qin Wang, Yidan Huang, Yalan Li, Yi Hong, Shoushi Wang, Han Lin, Hong Li und 11 weitere

British Journal of Anaesthesia · 2024

DOI: 10.1016/j.bja.2023.10.022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Anaesthesia, 2024. Verfasst von Yujun Zhang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Anaesthesia and Critical Care Medicine, Nationa…. Hauptthemen laut MEDLINE: Neuromuscular Blockade, gamma-Cyclodextrins, Neuromuscular Nondepolarizing Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Preliminary clinical trials of adamgammadex, a new cyclodextrin-based selective reversal agent, have demonstrated its efficacy in reversing neuromuscular block by rocuronium. METHODS: This multicentre, randomised, double-blind, positive-controlled, non-inferiority phase III clinical trial compared the efficacy and safety of adamgammadex and sugammadex. We randomised 310 subjects to receive adamgammadex (4 mg kg-1) or sugammadex (2 mg kg-1) at reappearance of the second twitch of the train-of-four (TOF), and standard safety data were collected. RESULTS: For the primary outcome, the proportion of patients with TOF ratio ≥0.9 within 5 min was 98.7% in the adamgammadex group vs 100% in the sugammadex group, with a point estimate and 95% confidence interval (CI) of 1.3% (-4.6%, +1.3%); the lower limit was greater than the non-inferiority margin of -10%. For the key secondary outcome, the median (inter quartile range) time from the start of administration of adamgammadex or sugammadex to recovery of TOF ratio to 0.9 was 2.25 (1.75, 2.75) min and 1.75 (1.50, 2.00) min, respectively. The difference was 0.50 (95% CI: 0.25, 0.50); the upper limit was lower than the non-inferiority margin of 5 min. In addition, there were no inferior results observed in secondary outcomes. Adamgammadex had a lower incidence of adverse drug reactions compared with sugammadex (anaphylactic reaction, recurarisation, decreased heart rate, and laryngospasm; P=0.047). CONCLUSIONS: Adamgammadex was non-inferior to sugammadex with a possible lower incidence of adverse drug reactions compared with sugammadex. Adamgammadex may have a potential advantage in terms of its overall risk-benefit profile. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000039525. Registered October 30, 2020. https://www.chictr.org.cn/showproj.html?proj=56825.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromuscular Blockadegamma-CyclodextrinsNeuromuscular Nondepolarizing AgentsDrug-Related Side Effects and Adverse ReactionsHumansSugammadexRocuroniumAndrostanols

Stichwörter der Autor:innen

adamgammadexadverse drug reactionneuromuscular blocking agentpharmacodynamicsreversalrocuroniumsugammadex

Substanzen

SugammadexRocuroniumgamma-CyclodextrinsNeuromuscular Nondepolarizing AgentsAndrostanols

Autor:innen und Institutionen

  • Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Anaesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of…
  • Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Anaesthesiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Anaesthesiology, Second People's Hospital of Neijiang, Neijiang, China.
  • Department of Anaesthesiology, Central Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Ji'nan, China.
  • Department of Anaesthesiology, Liuzhou People's Hospital, Liuzhou, China.

Zitieren

APA

Zhang, Y., Jiang, Y., Lei, Q., Li, C., Jin, S., Wang, Q., Huang, Y., Li, Y., Hong, Y., Wang, S., Lin, H., Li, H., Ou, Y., Zou, X., Sun, Q., Guo, Q., Chen, Z., Min, S., Qi, Y., …, & Zhang, W. (2024). Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2023.10.022

Vancouver

Zhang Y, Jiang Y, Lei Q, Li C, Jin S, Wang Q, et al. Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. British Journal of Anaesthesia. 2024. doi:10.1016/j.bja.2023.10.022

BibTeX
@article{Zhang2024,
  author = {Zhang, Yujun and Jiang, Yingying and Lei, Qian and Li, Chaoyu and Jin, Shu'an and Wang, Qin and Huang, Yidan and Li, Yalan and Hong, Yi and Wang, Shoushi and Lin, Han and Li, Hong and Ou, Yangwen and Zou, Xiaohua and Sun, Qiang and Guo, Qulian and Chen, Zhigang and Min, Su and Qi, Youmao and Jie, Qing and Liu, Jin and Liu, Bin and Zhang, Wensheng},
  title = {Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block},
  journal = {British Journal of Anaesthesia},
  year = {2024},
  doi = {10.1016/j.bja.2023.10.022}
}
Kostenlos starten →